BICO Group: Business Overview, Financials & Competitive Analysis
BICO Group scores 7/10 on the AskCyborg Cyborg Score (Strong). BICO is a high-growth biotech infrastructure play addressing significant market opportunities in drug discovery automation and regenerative medicine, backed by strong institutional traction but facing execution complexity. BICO holds a clear market leadership position in 3D bioprinting with extensive institutional adoption across pharma and academic labs. Strategic acquisition strategy (MatTek.
What is BICO Group's industry? BICO Group (bico.com) operates in Biotech/Life Sciences Infrastructure - 3D Bioprinting, Lab Automation & Cell Culture. AskCyborg classifies BICO Group under Biotech/Life Sciences Infrastructure - 3D Bioprinting, Lab Automation & Cell Culture in its company registry.
BICO Group is a Swedish bioconvergence company that designs and supplies technologies and services to enhance biology research, focusing on commercializing technologies for life science research and bioprinting. With ...
Cyborg Score thesis
BICO is a high-growth biotech infrastructure play addressing significant market opportunities in drug discovery automation and...
Read the full analyst-debate transcript →Get the Latest BICO Group Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBICO Group Overview
Pro stress-test →BICO Group is a Swedish bioconvergence company that designs and supplies technologies and services to enhance biology research, focusing on commercializing technologies for life science research and bioprinting. With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies.
Strategic Profile
Pro stress-test →BICO transitioned to a bioconvergence company in 2020, expanding its focus from bioprinting to broader life sciences technology and industrial solutions. Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development. BICO is a prominent player in the global 3D bioprinting market, boasting a diversified portfolio of products for 3D cell cultures for high-throughput drug screening and printing of human tissues and organs.
Competitive Landscape
Pro stress-test →3D Systems holds strong position in 3D bioprinting market with strong product portfolio of bioprinters, bioinks and software, emphasizing collaboration with governments and non-profit organizations. Other competitors include Merck KGaA, Organovo Holdings, Collplant Biotechnologies, regenHU, Aspect Biosystems, and Rokit Healthcare. BICO differentiates through diversified bioconvergence platform combining robotics, AI, genomics and bioprinting.
Industry Context
BICO Group operates in Biotech/Life Sciences Infrastructure - 3D Bioprinting, Lab Automation & Cell Culture.
Key facts
Founded: 2016 · Headquarters: Gothenburg, Sweden · Employees: N/A · Revenue: N/A · Market cap: N/A